Literature DB >> 12478876

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression.

Heinz Grunze1, Siegfried Kasper, Guy Goodwin, Charles Bowden, David Baldwin, Rasmus Licht, Eduard Vieta, Hans-Jürgen Möller.   

Abstract

These practice guidelines for the biological, mainly pharmacological treatment of bipolar depression were developed by an international task force of the World Federation of Societies of Biological Psychiatry (WFSBP). Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of bipolar depression. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, and from recent proceedings of key conferences and various national and international treatment guidelines. Their scientific rigor was categorised into four levels of evidence (A-D). As these guidelines are intended for clinical use, the scientific evidence was not only graded, but also commented on by the experts of the task force to ensure practicability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478876     DOI: 10.3109/15622970209150612

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  33 in total

1.  How close is evidence to truth in evidence-based treatment of mental disorders?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-22       Impact factor: 5.270

Review 2.  [Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making].

Authors:  H-J Möller; W Maier
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

3.  Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.

Authors:  Hans-Jürgen Möller; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

Review 4.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 5.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

6.  Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

Review 7.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

8.  [Electroconvulsive therapy at the Department of Psychiatry and Psychotherapy, University of Munich. Development during the years 1995-2002].

Authors:  T C Baghai; A Marcuse; H-J Möller; R Rupprecht
Journal:  Nervenarzt       Date:  2005-05       Impact factor: 1.214

Review 9.  Quetiapine: a review of its use in the treatment of bipolar depression.

Authors:  Gillian M Keating; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  The role of lamotrigine in the management of bipolar disorder.

Authors:  Felicity Ng; Karen Hallam; Nellie Lucas; Michael Berk
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.